Tech Company Financing Transactions
Novasenta Funding Round
On 8/1/2022, Novasenta announced $40 million in Series A funding from UPMC Enterprises and private investors.
Transaction Overview
Company Name
Announced On
8/1/2022
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
UPMC Enterprises (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its pipeline of antibody-based therapeutics and expand its proprietary computational platforms for target discovery, while continuing to recruit top talent.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
350 Technology Dr. 501
Pittsburgh, PA 15219
USA
Pittsburgh, PA 15219
USA
Phone
Website
Email Address
Overview
Novasenta discovers novel therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer. Single-cell level analysis of high-quality, human tumor samples combined with the advanced data mining abilities of our research and computational biology teams accelerate the path from discovery to patient.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mani Mohindru
Vice President
James Brown
Vice President
Pallavi Tawde
VP - Operations
Daniele Crisi-Couchenour
VP - R & D
Jiayi Yu
Browse more venture capital transactions:
Prev: 8/1/2022: Enabld Technologies venture capital transaction
Next: 8/1/2022: OrBit Markets venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs